Gelatinase B is present in the cerebrospinal fluid during experimental autoimmune encephalomyelitis and cleaves myelin basic protein

Journal of Neuroscience Research

Volumn 36, Issue 4, 1993, Pages 432-440

  Gijbels, K ^a,c   Proost, P ^a   Masure, S ^a   Carton, H ^b   Billiau, A ^a   Opdenakker, G ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c STANFORD UNIVERSITY   (United States)

Author keywords

demyelination; gelatinase activity; multiple sclerosis

Indexed keywords

GELATINASE; MYELIN BASIC PROTEIN;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CEREBROSPINAL FLUID; CONTROLLED STUDY; DEMYELINATION; ENZYME ACTIVITY; ENZYME SYNTHESIS; EXPERIMENTAL MODEL; INFLAMMATORY INFILTRATE; MOLECULAR WEIGHT; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION;

AMINO ACID SEQUENCE; ANIMAL; BRAIN STEM; CEREBELLUM; COLLAGENASES; EDETIC ACID; ENCEPHALOMYELITIS, EXPERIMENTAL AUTOIMMUNE; GELATINASE B; GUINEA PIGS; MICE; MOLECULAR SEQUENCE DATA; MOLECULAR WEIGHT; MYELIN BASIC PROTEINS; PHENANTHROLINES; PROTEASE INHIBITORS; SPINAL CORD; SUPPORT, NON-U.S. GOV'T; TIME FACTORS;

EID: 0027368518     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.490360409     Document Type: Article

References (41)

1. Degradation of myelin basic protein by cerebrospinal fluid: Preservation of antigenic determinants under physiological conditions
2. Proteinase inhibitors suppress the development of experimental allergic encephalomyelitis
3. Degradation of basic protein in myelin by neutral proteases secreted by stimulated macrophages: A possible mechanism of inflammatory demyelination
4. Role of enzyme receptors and inhibitors in regulating proteolytic activity of macrophages
5. Proteolytic enzyme activity of blood leukocytes and cerebrospinal fluid in multiple sclerosis
6. Large scale preparation of myelin basic protein from central nervous tissue of several mammalian species
7. Production of B cell stimulatory factor‐2 and interferon‐γ in the central nervous system during viral meningitis and encephalitis
8. Encephalitogenic epitopes of myelin basic protein
9. Interferon beta 2/B‐cell stimulatory factor type 2 shares identity with monocyte‐derived hepatocyte‐stimulating factor and regulates the major acute phase protein response in liver cells
10. Induction of rat acute‐phase proteins by interleukin‐6 in vivo
11. Interleukin 6 production in the central nervous system during experimental autoimmune encephalomyelitis
12. Gelatinase in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological disorders
13. Allergic encephalomyelitis: Isolation and characterization of encephalitogenic peptides from the basic protein of bovine spinal cord
14. Cytokine accumulations in CSF of multiple sclerosis patients: Frequent detection of interleukin‐1 and tumor necrosis factor but not interleukin‐6
15. Electrophoretic analysis of plasminogen activators in polyacrylamide gels containing sodium dodecyl sulphate and copolymerised substrates
16. Elevated levels of the 26K human hybridoma growth factor (interleukin 6) in cerebrospinal fluid of patients with acute infection of the central nervous system
17. Neutral protease in cerebrospinal fluid from patients with multiple sclerosis and other neurological diseases
18. Suppressive effect of camostat mesilate (FOY 305) on acute experimental allergic encephalomyelitis (EAE)
19. Inhibition of murine relapsing remitting experimental autoimmune encephalomyelitis by immune tolerance to proteolipid protein and its encephalitogenic peptides
20. Spreading of T‐cell autoimmunity to cryptic determinants of an autoantigen
21. Hyperacute, neutrophilic, and localized forms of experimental allergic encephalomyelitis: A review
22. Recognition of peptides that are immunopethogenic but cryptic. Mechanisms that allow lymphocytes sensitized against cryptic peptides to initiate pathogenic autoimmune processes
23. Interleukin‐6 induces the synthesis of tissue inhibitor of metalloproteinases‐1/erythroid potentiating activity (TIMP‐1/EPA)
24. Studies on the ability of 65‐kDa and 92‐kDa tumor cell gelatinases to degrade type IV collagen
25. Cytokine levels in the cerebrospinal fluid and serum of patients with multiple sclerosis
26. Myelin basic protein speciation
27. Immunological aspects of demyelinating diseases
28. Human hepatoma cells produce an 85 kDa gelatinase regulated by phorbol 12‐myristate 13‐acetate
29. Purification and identification of 91‐kDa neutrophil gelatinase. Release by the activating peptide interleukin‐8
30. Cytokines and proteases in invasive processes: Molecular similarities between inflammation and cancer
31. Cytokinemediated regulation of human leukocyte gelatinases and role in arthritis
32. Natural human monocyte gelatinase and its inhibitor
33. Release of plasminogen activator and a calcium dependent metalloprotease from cultured sympathetic sensory neurons
34. Analysis of autoimmune demyelination. Its impact upon multiple sclerosis
35. TIMP‐2 reduces proteolytic opening of blood‐brain barrier by type IV collagenase
36. Characterization of a major encephalitogenic T‐cell epitope in SJL/J mice with synthetic oligopeptides of myelin basic protein
37. Interleukin 6 enhances the production of tissue inhibitor of metalloproteinases (TIMP) but not that of matrix metalloproteinases by human fibroblasts
38. Model systems for study of perturbations of myelin metabolism
39. The precursor of bone collagenase and its activation
40. Lymphocytes from SJL/J mice immunized with spinal cord respond selectively to a peptide of proteolipid protein and transfer relapsing demyelinating experimental autoimmune encephalomyelitis
41. Matrix metalloproteinases and their inhibitors in connective tissue remodeling